Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
The University of Texas MD Anderson Cancer Center · Heidelberg University · +7 more institutions
Indexed incrossrefpubmed
Abstract
Background
Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase.
Methods
A total of 532 patients with late--chronic-phase CML in whom previous therapy with interferon alfa had failed were treated with 400 mg of oral imatinib daily. Patients were evaluated for cytogenetic and hematologic responses. Time to progression, survival, and toxic effects were also evaluated.
Citation impact
2,030
total citations
- FWCI
- 80.72
- Percentile
- 100%
- References
- 26
Citations per year
Authors
12Topics & keywords
Topics
Keywords
- Medicine
- Imatinib mesylate
- Chronic myelogenous leukemia
- Imatinib
- Philadelphia chromosome
- Internal medicine
- Tyrosine-kinase inhibitor
- Gastroenterology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.